Plant Cell Culture-Derived Saponin Adjuvant Enhances Immune Response Against a Stabilized Human Metapneumovirus Pre-Fusion Vaccine Candidate

被引：0

作者：

Swart, Maarten ^{[1
]}

Allen, Jessica ^{[2
]}

Reed, Brendan ^{[2
]}

Gil, Ana Izquierdo ^{[1
]}

Verspuij, Johan ^{[1
]}

Schmit-Tillemans, Sonja ^{[1
]}

Chakkumkal, Anish ^{[1
]}

Findeis, Mark ^{[2
]}

Hafner, Angela V. ^{[2
,3
]}

Harjivan, Chandresh ^{[2
]}

Kurnat, Rebecca ^{[2
]}

Kuipers, Harmjan ^{[1
]}

Zahn, Roland ^{[1
]}

Brandenburg, Boerries ^{[1
]}

机构：

[1] Johnson & Johnson, Janssen Vaccines & Prevent, NL-2333 CN Leiden, Netherlands

[2] SaponiQx, 3 Forbes Rd, Lexington, MA 02421 USA

[3] Agenus Inc, 3 Forbes Rd, Lexington, MA 02421 USA

来源：

VACCINES | 2024年 / 12卷 / 12期

关键词：

human metapneumovirus; HMPV; Pneumoviridae family viruses; subunit vaccine; adjuvant; QS-21; cpcQS-21; Saponin; AS01; INFECTION; CHILDREN; BURDEN; QS-21;

D O I：

10.3390/vaccines12121435

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Human metapneumovirus (HMPV) is a significant respiratory pathogen, particularly in vulnerable populations. Background: No vaccine for the prevention of HMPV is currently licensed, although several subunit vaccines are in development. Saponin-based adjuvant systems (AS), including QS-21, have transformed the field of subunit vaccines by dramatically increasing their potency and efficacy, leading to the development of several licensed vaccines. However, naturally sourced tree bark-extracted QS-21 faces supply and manufacturing challenges, hindering vaccine development. Objective: This study reports on an alternative plant cell culture system for the consistent production of highly pure QS-21. Method: We evaluated the efficacy of cultured plant cell (cpc)-produced QS-21 in a novel HMPV vaccine, formulating a recombinant pre-fusion stabilized HMPV F protein (preF) with cpcQS-21 and a synthetic toll-like receptor 4 (TLR4) agonist adjuvant formulation. Results: In mice, TLR4 agonist containing adjuvant formulations with plant cell-produced QS-21 performed equally to licensed adjuvant AS01 containing tree-bark-extracted QS-21 and demonstrated a significant increase in immunogenicity against HMPV preF compared to the unadjuvanted control. Conclusion: Our findings pave the way for a reliable, scalable, and sustainable source of pure QS-21, enabling the development of highly effective HMPV and other vaccines with significant public health impact.

引用

页数：9

共 26 条

[1] van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., Osterhaus A.D., A newly discovered human pneumovirus isolated from young children with respiratory tract disease, Nat. Med, 7, pp. 719-724, (2001)
[2] Panda S., Mohakud N.K., Pena L., Kumar S., Human metapneumovirus: Review of an important respiratory pathogen, Int. J. Infect. Dis, 25, pp. 45-52, (2014)
[3] Wang X., Li Y., Deloria-Knoll M., Madhi S.A., Cohen C., Ali A., Basnet S., Bassat Q., Brooks W.A., Chittaganpitch M., Et al., Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: A systematic review and modelling study, Lancet Glob Health, 9, pp. e33-e43, (2021)
[4] Edwards K.M., Zhu Y., Griffin M.R., Weinberg G.A., Hall C.B., Szilagyi P.G., Staat M.A., Iwane M., Prill M.M., Williams J.V., Et al., Burden of human metapneumovirus infection in young children, N. Engl. J. Med, 368, pp. 633-643, (2013)
[5] Englund J.A., Boeckh M., Kuypers J., Nichols W.G., Hackman R.C., Morrow R.A., Fredricks D.N., Corey L., Brief communication: Fatal human metapneumovirus infection in stem-cell transplant recipients, Ann. Intern. Med, 144, pp. 344-349, (2006)
[6] Bonam S.R., Partidos C.D., Halmuthur S.K.M., Muller S., An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy, Trends Pharmacol. Sci, 38, pp. 771-793, (2017)
[7] Pulendran B., SArunachalam P., O'Hagan D.T., Emerging concepts in the science of vaccine adjuvants, Nat. Rev. Drug Discov, 20, pp. 454-475, (2021)
[8] den Brok M.A.-O., Bull C., Wassink M., de Graaf A.M., Wagenaars J.A., Minderman M., Thakur M., Amigorena S., Rijke E.O., Schrier C.C., Et al., Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation, Nat. Commun, 7, (2016)
[9] Ragupathi G., Gardner Jr Fau-Livingston P.O., Livingston Po Fau-Gin D.Y., Gin D.Y., Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer, Expert. Rev. Vaccines, 10, pp. 463-470, (2011)
[10] Kensil C.R., Patel U., Lennick M., Marciani D., Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex, J. Immunol, 146, pp. 431-437, (1991)

← 1 2 3 →